Inozyme Pharma Inc
INZY3.945USD
-0.005-0.13%
시장 운영 시간 （ET）시세는 15분 지연됩니다
254.34M시가총액
손실P/E TTM
자세한 내용은 Inozyme Pharma Inc 회사
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
회사 정보
회사 코드INZY
회사 이름Inozyme Pharma Inc
상장일Jul 24, 2020
설립일2015
CEODr. Douglas A. (Doug) Treco, Ph.D.
직원 수67
유형Ordinary Share
회계 연도 종료Jul 24
주소321 Summer Street
도시BOSTON
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02210
전화18573304340
웹사이트https://www.inozyme.com/
회사 코드INZY
상장일Jul 24, 2020
설립일2015
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Axel Bolte
Mr. Axel Bolte
Director
Director
266.70K
--
Dr. Matthew Winton, Ph.D.
Dr. Matthew Winton, Ph.D.
Chief Operations Officer
Chief Operations Officer
7.39K
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Sarah M. Bhagat, Ph.D.
Dr. Sarah M. Bhagat, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Lead Independent Director
Lead Independent Director
--
--
Dr. Douglas A. (Doug) Treco, Ph.D.
Dr. Douglas A. (Doug) Treco, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Lynne Sullivan, CPA
Ms. Lynne Sullivan, CPA
Independent Director
Independent Director
--
--
Mr. Erik Harris
Mr. Erik Harris
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Axel Bolte
Mr. Axel Bolte
Director
Director
266.70K
--
Dr. Matthew Winton, Ph.D.
Dr. Matthew Winton, Ph.D.
Chief Operations Officer
Chief Operations Officer
7.39K
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Sarah M. Bhagat, Ph.D.
Dr. Sarah M. Bhagat, Ph.D.
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주주
업데이트 시간: Fri, May 16
업데이트 시간: Fri, May 16
주주 통계
유형
주주 통계
주주
비율
Longitude Capital Management Co., LLC
9.05%
Adage Capital Management, L.P.
7.99%
Pivotal Bioventure Partners Investment Advisor LLC
6.96%
Sofinnova Investments, Inc
6.63%
Affinity Asset Advisors LLC
5.99%
Other
63.38%
주주 통계
주주
비율
Longitude Capital Management Co., LLC
9.05%
Adage Capital Management, L.P.
7.99%
Pivotal Bioventure Partners Investment Advisor LLC
6.96%
Sofinnova Investments, Inc
6.63%
Affinity Asset Advisors LLC
5.99%
Other
63.38%
유형
주주
비율
Venture Capital
29.01%
Hedge Fund
28.61%
Investment Advisor/Hedge Fund
12.21%
Investment Advisor
11.67%
Research Firm
0.85%
Corporation
0.69%
Private Equity
0.68%
Individual Investor
0.54%
Bank and Trust
0.10%
Other
15.65%
기관 주식 보유
업데이트 시간: Tue, Mar 4
업데이트 시간: Tue, Mar 4
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
216
60.54M
94.21%
-7.78M
2024Q4
214
60.27M
93.82%
-9.91M
2024Q3
191
62.40M
99.19%
-7.69M
2024Q2
189
61.61M
98.84%
-3.38M
2024Q1
182
57.68M
93.47%
-8.16M
2023Q4
168
57.62M
93.40%
-5.18M
2023Q3
173
55.08M
89.40%
+6.47M
2023Q2
167
38.83M
84.32%
-10.19M
2023Q1
159
36.61M
84.56%
-4.82M
2022Q4
151
33.67M
83.45%
-6.75M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Longitude Capital Management Co., LLC
5.84M
9.09%
--
--
Apr 22, 2024
Adage Capital Management, L.P.
5.16M
8.03%
-513.63K
-9.05%
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
4.49M
7%
--
--
Dec 31, 2024
Sofinnova Investments, Inc
4.28M
6.66%
--
--
Dec 31, 2024
Affinity Asset Advisors LLC
3.97M
6.18%
+1.15M
+40.75%
Dec 31, 2024
Rock Springs Capital Management LP
3.86M
6.01%
+59.10K
+1.55%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.49M
5.43%
+313.70K
+9.87%
Dec 31, 2024
The Vanguard Group, Inc.
2.63M
4.1%
+8.91K
+0.34%
Dec 31, 2024
New Enterprise Associates (NEA)
2.44M
3.79%
--
--
Dec 31, 2024
Samsara BioCapital, LLC
1.56M
2.43%
--
--
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
iShares Russell 3000 ETF
0%
iShares Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
더 보기
Invesco Nasdaq Biotechnology ETF
비율0.01%
ProShares Ultra Nasdaq Biotechnology
비율0.01%
iShares Micro-Cap ETF
비율0.01%
iShares Russell 3000 ETF
비율0%
iShares Russell 2000 ETF
비율0%
Dimensional US Core Equity 1 ETF
비율0%
Fidelity Nasdaq Composite Index ETF
비율0%
Global X Russell 2000 ETF
비율0%
Global X Russell 2000 Covered Call ETF
비율0%
DFA Dimensional US Core Equity Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
